Charts seem to point to a $6.40-$6.80 range in the short term for SNTA. An even higher surge may be realized with the upcoming ENCHANT presentation on Thursday, December 12th. I won't even guess where the price will go after that....but it could be a second surge in stock price for SNTA. The science behind heat shock protein inhibitors interruption of crucial steps to the survival of tumor progression is solid and with mechanisms of action becoming clear, ganetespib has a much higher potential for FDA approval. The key to ganetespib success is the established safety profile coupled with the efficacy data that will be coming out soon. Good luck longs....it sure looks like we are about to have a great breakout in the next few weeks and months ahead.
We may have Enchant results on Thursday and the Harvard combo study results on Friday. We could be talking a two day surge on the catalyst date. Something to keep in mind :) If that happens we really might see 10
Agreed....and one of the "hidden" values of ganetespib is the combination treatment value. Ganetespib may end up being a phenomenal combination product for numerous cancers. Synergistic success may spell huge partnership value for a number of partnerships. This potential is only for the raw drug. The HDC platform products open new doors and even more partnerships. It is a very exciting time for early investors in Synta Pharmaceuticals.